Skip to main content

Advertisement

SpringerLink
Log in

Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

In this paper, we report a study on the clinical relevance of prothymosin-α expression and its correlation with intratumoral Foxp3+ and CD8+ lymphocytes (Foxp3+TIL and CD8+TIL) in bladder cancer patients. We used immunohistochemical staining for prothymosin-α, Foxp3, and CD8 on 101 tumor specimens harvested by endoscopic resection. The results were correlated with clinicopathological variables and clinical outcome in bladder cancer patients, particularly in 73 patients with superficial disease, using the log-rank test and Cox proportional hazard model. Overall, of the tumors, 30 % were negative, 34 % showed nuclear, and 37 % showed cytoplasmic prothymosin-α expression. Foxp3+TILs were detected in 11 % of patients (nonnuclear vs. nuclear, p = 0.096). Patients with a history of urothelial carcinoma have a higher frequency of nonnuclear prothymosin-α expression than those without (p = 0.016, chi-square test). By univariate and multivariate analyses of cases with superficial disease, grade and stage were identified as independent predictors for recurrence-free survival (p = 0.016 and 0.016, respectively). Higher stage and nonnuclear prothymosin-α expression independently predict shorter progression-free survival (p = 0.006 and 0.043, respectively). The presence of Foxp3+TILs was significantly associated with disease progression by univariate analysis (p = 0.022), but not by multivariate analysis (p = 0.147). In vitro assays showed that J82 cells which express ectopically nuclear prothymosin-α exhibit higher growth rate and secrete less TGF-β1 than those with cytoplasmic expression or control cells. Altogether, prothymosin-α expression is a determinant of disease progression in superficial bladder cancer. Foxp3+TILs tend to be found more often in bladder cancer with nonnuclear prothymosin-α expression. Future study is required to unravel their interaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725

    Article  CAS  PubMed  Google Scholar 

  3. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584–594

    Article  PubMed  Google Scholar 

  4. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018

    Article  CAS  PubMed  Google Scholar 

  5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  6. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7:10

    PubMed Central  PubMed  Google Scholar 

  7. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625

    Article  CAS  PubMed  Google Scholar 

  8. Wu CL, Shiau AL, Lin CS (1997) Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci 61:2091–2101

    Article  CAS  PubMed  Google Scholar 

  9. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J et al (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299:223–226

    Article  CAS  PubMed  Google Scholar 

  10. Vareli K, Frangou-Lazaridis M, van der Kraan I, Tsolas O, van Driel R (2000) Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. Exp Cell Res 257:152–161

    Article  CAS  PubMed  Google Scholar 

  11. Klimentzou P, Drougou A, Fehrenbacher B, Schaller M, Voelter W, Barbatis C et al (2008) Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody. J Histochem Cytochem 56:1023–1031

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX (2007) Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol 33:195–201

    Article  CAS  PubMed  Google Scholar 

  13. Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M (1995) Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol Immunother 40:410–418

    Article  CAS  PubMed  Google Scholar 

  14. Cordero OJ, Sarandeses C, Nogueira M (1995) Prothymosin alpha receptors on lymphocytes. J Interferon Cytokine Res 15:731–737

    Article  CAS  PubMed  Google Scholar 

  15. Skopeliti M, Iconomidou VA, Derhovanessian E, Pawelec G, Voelter W, Kalbacher H et al (2009) Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol Immunol 46:784–792

    Article  CAS  PubMed  Google Scholar 

  16. Jou YC, Tsai YS, Hsieh HY, Chen SY, Tsai HT, Chen KJ et al (2013) Plasma thymosin-alpha1 level as a potential biomarker in urothelial and renal cell carcinoma. Urol Oncol 31(8):1806–1811. doi:10.1016/j.urolonc.2012.03.011

    Article  CAS  PubMed  Google Scholar 

  17. Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, Tsai HT (2006) Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 67:294–299

    Article  PubMed  Google Scholar 

  18. Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL et al (2009) Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology 74:951–957

    Article  PubMed  Google Scholar 

  19. Lin CT, Tung CL, Tsai YS, Shen CH, Jou YC, Yu MT et al (2012) Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. Urol Oncol 30:680–687

    Article  PubMed  Google Scholar 

  20. Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT et al (2009) Aberrant prothymosin-alpha expression in human bladder cancer. Urology 73:188–192

    Article  PubMed  Google Scholar 

  21. Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A et al (2011) Foxp3 and survival in urinary bladder cancer. BJU Int 108:1672–1678

    Article  CAS  PubMed  Google Scholar 

  22. Lukashev DE, Chichkova NV, Vartapetian AB (1999) Multiple tRNA attachment sites in prothymosin alpha. FEBS Lett 451:118–124

    Article  CAS  PubMed  Google Scholar 

  23. Panneerselvam C, Haritos AA, Caldarella J, Horecker BL (1987) Prothymosin alpha in human blood. Proc Natl Acad Sci U S A 84:4465–4469

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Dominguez F, Magdalena C, Cancio E, Roson E, Paredes J, Loidi L et al (1993) Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer 29A:893–897

    Article  CAS  PubMed  Google Scholar 

  25. Cordero OJ, Sarandeses CS, Lopez JL, Cancio E, Regueiro BJ, Nogueira M (1991) Prothymosin alpha enhances interleukin 2 receptor expression in normal human T-lymphocytes. Int J Immunopharmacol 13:1059–1065

    Article  CAS  PubMed  Google Scholar 

  26. Su BH, Tseng YL, Shieh GS, Chen YC, Shiang YC, Wu P et al (2013) Prothymosin alpha overexpression contributes to the development of pulmonary emphysema. Nat Commun 4:1906

    Article  PubMed Central  PubMed  Google Scholar 

  27. Li KJ, Shiau AL, Chiou YY, Yo YT, Wu CL (2005) Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease. Kidney Int 67:1710–1722

    Article  CAS  PubMed  Google Scholar 

  28. Matsunaga H, Ueda H (2010) Stress-induced non-vesicular release of prothymosin-alpha initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ 17:1760–1772

    Article  CAS  PubMed  Google Scholar 

  29. Enkemann SA, Wang RH, Trumbore MW, Berger SL (2000) Functional discontinuities in prothymosin alpha caused by caspase cleavage in apoptotic cells. J Cell Physiol 182:256–268

    Article  CAS  PubMed  Google Scholar 

  30. Evstafieva AG, Belov GA, Kalkum M, Chichkova NV, Bogdanov AA, Agol VI et al (2000) Prothymosin alpha fragmentation in apoptosis. FEBS Lett 467:150–154

    Article  CAS  PubMed  Google Scholar 

  31. Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A et al (2006) The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Cancer Immunol Immunother 55:1247–1257

    Article  CAS  PubMed  Google Scholar 

  32. Olsson CA, Rao CN, Menzoian JO, Byrd WE (1972) Immunologic unreactivity in bladder cancer patients. J Urol 107:607–609

    CAS  PubMed  Google Scholar 

  33. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH (2007) Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 177:353–358

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Science Council of Taiwan (Grants NSC 97-2314-B-006-051-MY3 and 98-2314-B-006-051-MY2) and Chia-Yi Christian Hospital (Grants 97-07 and 98-07).

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, College of Medicine and Hospital, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan

    Yuh-Shyan Tsai, Hsin-Tzu Tsai, Chen-Li Lai & Tzong-Shin Tzai

  2. Department of Urology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan

    Yeong-Chin Jou, Chang-Te Lin & Cheng-Huang Shen

  3. Department of Pathology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan

    Chun-Liang Tung

  4. Department of Biochemistry, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan

    Chao-Liang Wu

  5. Department of Medical Research, Chia-Yi Christian Hospital, Chia-Yi, Taiwan

    Syue-Yi Chen

Authors
  1. Yuh-Shyan Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeong-Chin Jou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chun-Liang Tung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang-Te Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheng-Huang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Syue-Yi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hsin-Tzu Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chen-Li Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chao-Liang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tzong-Shin Tzai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yuh-Shyan Tsai or Tzong-Shin Tzai.

Additional information

Both Yeong-Chin Jou and Yuh-Shyan Tsai contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

(DOC 183 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, YS., Jou, YC., Tung, CL. et al. Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer. Virchows Arch 464, 717–724 (2014). https://doi.org/10.1007/s00428-014-1578-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1578-6

Keywords

Search

Navigation